Background Aromatase inhibitors prevent breast cancer in postmenopausal women at high risk of the disease but are associated with accelerated bone loss. We assessed eff ectiveness of oral risedronate for prevention of reduction in bone mineral density (BMD) after 3 years of follow-up in a subset of patients in the IBIS-II trial.
Introduction
Oestrogen has a major role in the regulation of skeletal homoeostasis, and therefore physiological decreases in oestrogen concentrations place postmenopausal women at high risk of osteoporosis (low bone mineral density [BMD] ). Reduction in BMD in the fi rst 7 years after the menopause is 1-3% per year at the spine and 1-2% per year at the hip. 1 Bone loss can be treated or prevented with bisphosphonates, which increase BMD by inhibition of osteoclast-mediated bone resorption. 2, 3 This risk of BMD loss, and therefore fractures, is aggravated in postmenopausal women with breast cancer who are given an aromatase inhibitor as part of their treatment. 4, 5 Aromatase inhibitors suppress oestrogen concentrations in postmenopausal women by inhibition of the conversion of androgens to oestrogens by the aromatase enzyme in soft tissues, especially fat. Studies from large adjuvant trials show signifi cant BMD decreases and higher fracture rates in women receiving aromatase inhibitors compared with women on tamoxifen. [6] [7] [8] [9] In the ATAC trial, anastrozole signifi cantly decreased BMD at the lumbar spine (6·1%) and total hip (7·2%) after 5 years of follow-up, whereas a signifi cant increase in BMD was noted with tamoxifen. 6 Similarly, the results from the BIG 1-98 confi rmed a signifi cant BMD loss and an increased fracture rate with letrozole compared with tamoxifen. 10 Most of the studies investigating the eff ect of aromatase inhibitors on bone density have been done in postmenopausal women with early breast cancer receiving adjuvant tamoxifen as a comparison group. Tamoxifen has a benefi cial eff ect on BMD and it is therefore diffi cult to determine the true eff ect of aromatase inhibitors on BMD.
Two large prevention trials 11, 12 comparing an aromatase inhibitor with placebo in postmenopausal women at high risk of development of breast cancer have recently reported their main fi ndings. The MAP.3 trial, 11 which investigated exemestane for the prevention of breast cancer, reported a signifi cant BMD loss at the lumbar spine and total hip with exemestane compared with placebo after 2 years of follow-up. 13 Overall, no increases in fractures with exemestane were reported, but the follow-up of 35 months was too short to make a fi rm conclusion about this endpoint. The IBIS-II trial 12 compared anastrozole with placebo in postmenopausal women at high risk of development of breast cancer and noted a signifi cant reduction in breast cancer with anastrozole. Here we report the fi rst results of a perprotocol analysis of the placebo-controlled IBIS-II bone substudy, which assesses the eff ect of 3 years of risedronate on BMD in postmenopausal women with healthy bone density, osteopenia, or osteoporosis.
Methods

Study design and participants
The IBIS-II trial recruited 3864 healthy, postmenopausal women at increased risk of breast cancer and randomly allocated them to receive either 1 mg/day oral anastrozole or matching placebo. 12 Eligible women were off ered the opportunity to enter a bone substudy. Eligibility criteria for the main IBIS-II study have been summarised in detail elsewhere. 12 In brief, postmenopausal women aged 40-70 years were recruited from 44 centres from seven countries. Study sites were those in IBIS-II that consented to do dual energy x-ray absorptiometry (DXA) scans as part of the follow-up trial (appendix) and deemed postmenopausal when they were aged 60 years or older; had had a bilateral oophorectomy; were younger than 60 years, but had a uterus and amenorrhoea for at least 12 months; or were younger than 60 years, had no uterus, and had a concentration of follicle stimulating hormone of greater than 30 IU/L. Exclusion criteria for the main trial included premenopausal status, any previous diagnosis of invasive cancers, present use of selective oestrogen receptor modulators for more than 6 months, intention to continue with hormone-replacement therapy, evidence of severe osteoporosis (T score less than -4·0), and lack of physiological or psychological fi tness. Women in the bone substudy were enrolled and stratifi ed into three groups according to the lowest baseline T score at either femoral neck or lumbar spine. Women with healthy T score (at least -1·0) were entered into stratum I. Women who were osteopenic (T score at least -2·5 but less than -1·0) were entered into stratum II. Finally, osteoporotic women with a T score of less than -2·5 but greater than -4·0 or those with one to two low trauma fragility fractures (as assessed by spinal radiographs) were entered into stratum III. Spinal radiographs within the 2 years before randomisation were used to rule out low trauma fractures. Women were advised to take vitamin D and calcium supplements, but no specifi c doses were specifi ed or required by study protocol. Exclusion criteria for the bone substudy included previous bilateral hip fractures or any type of metabolic bone disease. Furthermore, women who had regularly taken medication aff ecting bone metabolism within the past 12 months before study entry were also excluded. Finally, women who had a T score of less than -4·0 and those with more than two low trauma fractures, were excluded from the bone substudy and referred for further management. The trial was approved by the UK North West Multicentre Research Ethics Committee and was done in accordance with the Declaration of Helsinki, under the principles of good clinical practice. Participants provided written informed consent.
Randomisation and masking
Women in stratum II were randomly assigned to receive risedronate (35 mg/week) or matched placebo. Randomisation was done with randomly chosen blocks of size six, eight, or ten to maintain balance and was not stratifi ed. The non-consecutive allocation sequence was generated by the IBIS-II programmer before the study started who also assigned the interventions to all women. All IBIS-II personnel, participants, and clinicians were masked to treatment allocation and only the IBIS-II trial statistician (IS) had access to unmasked data.
Procedures
All women entering the main IBIS-II study were required to have a DXA scan before study entry for stratifi cation See Online for appendix and exclusion purposes. In the bone substudy, BMD was further assessed by follow-up DXA scans at the lumbar spine and total hip at 12, 36, and 60 months. Women who had a BMD loss of 6% or more at the 12 month visit were required to have a safety DXA scan at 24 months of follow-up. Similarly, women with a BMD loss of more than 10% at 36 months had a safety scan at 48 months, and those with a BMD loss of more than 16% at the 60 months visit had an interval scan at 72 months.
We calculated T scores with either the Lunar 14 or Hologic 15 manufacturer's reference ranges for the lumbar spine (L1 to L4) and the National Health and Nutrition Examination Survey (NHANES) III reference range for the femoral neck region. 16 All baseline and follow-up DXA scans were reviewed centrally by two clinical scientists with expertise in bone densitometry (GMB and RP) to ensure quality assurance. Regular phantom reports from all participating centres were reviewed and investigators were requested to use the same DXA machine whenever possible throughout the study.
Women in stratum I were monitored only. Women in stratum II of the bone substudy were randomly allocated to receive either 35 mg/week oral risedronate or matching placebo for 5 years. All women in stratum III (osteoporotic women) received oral risedronate (35 mg/week) for 5 years. Women in strata II and III were advised to take their allocated risedronate or matching placebo in an upright position upon waking in the morning on an empty stomach, and not to consume anything apart from water within the next 30 min to minimise risk of inactivation of the drug or oesophageal irritation. Women were allowed to have a dose reduction (ie, alternate weeks) or go on treatment holiday from risedronate if they developed severe adverse events potentially related to the trial medication.
For biomarker analyses, a 10 mL urine sample from the second void was collected at baseline and 12 months. We measured N-telopeptide of type I collagen (NTx) levels with the Ortho Clinical Diagnostics automated immunoassay (High Wycombe, UK). The interassay coeffi cient of variation for NTx was 6·4%. NTx was expressed as a ratio to creatinine (nmol bone collagen equivalent:mmol creatinine) and the interassay coeffi cient of variation for creatinine was 1·8%.
Outcomes
The primary objective of this analysis was to compare the eff ect of risedronate versus placebo on BMD between baseline and 3 years at both the lumbar spine and total hip in women taking anastrozole in stratum II. Secondary endpoints included the eff ect of anastrozole versus placebo at the total hip and lumbar spine on BMD in women in stratum I and stratum II who had not been randomly allocated to risedronate at 3 years; the eff ect of anastrozole versus placebo on BMD at the total hip and lumbar spine in women in stratum III at 3 years; and changes from baseline in biochemical markers (NTx to creatinine ratio) between baseline and 12 months of follow-up in all three strata.
Statistical analysis
All analyses were done on a per-protocol basis, in which women were included only if a baseline and 36 month DXA scan were available. In stratum II, our power calculations were designed to detect a diff erence of 1·6% between risedronate and placebo in women randomly allocated to anastrozole with 90% power. Power calculations for stratum I aimed to detect a diff erence of 1·4% between anastrozole and placebo with 90% power. Similar assumptions were made for women in stratum III, in which all women received risedronate.
Initial calculations suggested that we needed 500 women per strata. Recruiting osteoporotic women was diffi cult (number not achieved) whereas recruiting women with healthy bone was unproblematic. We thus entered postmenopausal women into the bone substudy until we had recruited 500 women into stratum II, which was needed to achieve power for primary objective. This analysis focuses on BMD changes between baseline and 36 months. Women ceased participation in the bone substudy if one of the following events occurred: withdrawal from main study, development of breast cancer, death, and if rapid bone loss occurred. These women were excluded from this analysis. We assessed normal distribution of all continuous variables with histograms and diagnostic distribution plots. All main results are expressed as percentage mean BMD changes at the total hip or lumbar spine between baseline and 36 months with corresponding 95% CIs. BMD changes and diff erences between treatment groups were assessed using t tests for two independent samples with corresponding 95% CI. For the NTx to creatinine ratio analysis, we report the estimated median (95% CI) percentage change from baseline to 12 months. We report two-sided p values, based on normal approximation, and all CIs at the 95% level. Analyses were done with STATA version 12.1.
This trial is registered, number ISRCTN31488319.
Role of the funding source
Sanofi -Aventis and AstraZeneca provided anastrozole and matched placebo. The sponsor or funding bodies of this study had no role in study design, collection of data or material, data analysis, interpretation of the data, or writing of the manuscript. IS had full access to all raw data. IS, JC, and RE had fi nal responsibility to submit the report for publication.
Results
Between Feb 2, 2003, and Sept 30, 2010, we enrolled 1410 postmenopausal women into the bone substudy with a median follow-up of 3·0 years (IQR 2·95-3·09; fi gure 1). 761 (54%) women were stratifi ed into stratum I, 500 (35%) into stratum II, and 149 (11%) into stratum III. Baseline and 36 month DXA scans were available for 903 (64%) women, who were included in this analysis (fi gure 1). No further DXA scans were done for women who withdrew from the main IBIS-II study (199 in stratum I, 127 in stratum II, 32 in stratum III), developed breast cancer (28 in stratum I, 12 in stratum II, four in stratum III), or died (nine in stratum I, four in stratum II, three in stratum III; no deaths were treatment related), and these women were excluded from the analysis (fi gure 1). 256 (72%) of the 358 women who withdrew from the main IBIS-II study did so before the 12 month follow-up visit (126 in stratum I, 112 in stratum II, 18 in stratum III) and therefore were excluded from this analysis. 55 women had a BMD decrease of more than 6% at the 12 month follow-up (36 in stratum I, 17 in stratum II, and two in stratum III). 13 of these women did not continue with the trial medication and were therefore excluded from this analysis (eight in stratum I, fi ve in stratum II; fi gure 1). Only 76 (5%) of 1410 women withdrew from the bone substudy without fi rst withdrawing from the main study (23 in stratum I, 49 in stratum II, and four in stratum III). 
Data are median (IQR), n (%), or mean (SD). DXA=dual energy x-ray absorptiometry. HRT=hormone-replacement therapy. Baseline characteristics for women with available baseline and 36 month DXA scans are shown in table 1. The baseline characteristics between women all receiving anastrozole and randomly allocated to risedronate versus placebo were evenly distributed and we noted no major diff erences (table 1) . Similarly, for women in stratum I and II not receiving risedronate but randomly allocated to anastrozole versus placebo, we noted no substantial diff erences in baseline characteristics. Women in stratum III who were randomly allocated to receive placebo were older than were those randomly allocated to anastrozole (p=0·043; table 1). All other comparisons in this stratum were not substantially diff erent between treatment groups. We compared baseline demographics and BMD for women included in this analysis with those who were excluded. No major diff erences between these two groups were noted for all baseline characteristics (data not shown).
In the analysis of women in stratum II who had all received anastrozole and either risedronate or placebo, 150 (58%) of 260 women had baseline and 36 month DXA scans available for analysis (77 anastrozole/ risedronate vs 73 anastrozole/placebo). Women randomly allocated to anastrozole and receiving risedronate had a mean BMD increase of 1·1% (95% CI 0·2 to 2·1) at the lumbar spine after 36 months' follow-up compared with a mean decrease of -2·6% (-4·0 to -1·3) in those not receiving risedronate (p<0·0001; fi gure 2, appendix). We noted a linear decrease in BMD at the lumbar spine and total hip for women randomly allocated to anastrozole over 36 months' follow-up. Although BMD for the total hip decreased by only -0·7% (95% CI -1·6 to 0·2) for women on anastrozole and risedronate after 36 months' follow-up, the diff erence was signifi cant compared with women on only anastrozole, who had a decrease of -3·5% (-4·6 to -2·3; p=0·0001; fi gure 2, appendix).
In the analysis of women in stratum I and II who were not randomly allocated to risedronate and received only anastrozole or placebo, 652 (65%) of 1008 had baseline and 36 month DXA scans. We noted a linear decrease in mean BMD for all groups between baseline and 36 months, irrespective of main randomisation (fi gure 2). However, we noted a signifi cantly larger decrease at the lumbar spine or total hip for women randomly allocated to anastrozole compared with placebo (lumbar spine: -4·0% [95% CI -4·5 to -3·4] for anastrozole vs -1·2% [-1·7 to -0·7] for placebo, p<0·0001; total hip: -4·0% [-4·4 to -3·6] for anastrozole vs -1·8% [-2·1 to -1·4] for placebo; p=0·0001; fi gure 2, appendix).
In the analysis of women in stratum III who had all received risedronate and either anastrozole or placebo, 106 (71%) of 149 women had baseline and 36 month DXA scans. We noted the largest increase in mean percentage BMD at the lumbar spine for women randomly allocated to placebo (3·9% increase [95% CI 2·6 to 5·2]) whereas we noted a smaller increase for women randomly allocated to anastrozole (1·2% increase [-0·09 to 2·6]; p=0·006; fi gure 2, appendix). We noted a rapid increase in BMD with risedronate within the fi rst 12 months of follow-up at the lumbar spine (fi gure 2). For the total hip, we noted an increase in mean percentage BMD in both treatment groups, with a Second void morning urine samples were analysed for NTx and creatinine in 866 women in the bone substudy. 627 (72%) women had a sample available at baseline and 12 months and these samples were the basis for this analysis (table 2) . In stratum I, we noted a signifi cant median increase of almost 9% after 12 months in women randomly allocated to anastrozole, but no diff erence with placebo (table 2). The diff erence between treatment groups for the yearly change in NTx to creatinine ratio was signifi cant (p<0·0001; table 2). Women in stratum II who were randomly allocated to anastrozole but not to risedronate had a signifi cant median increase in NTx to creatinine ratio of almost 12% by 12 months of follow-up whereas those randomly allocated to placebo did not 
See appendix for a breakdown of adverse events by severity. show a signifi cant change in this marker (table 2) . By contrast, women who were randomly allocated to receive risedronate in stratum II had signifi cant median decreases in NTx to creatinine ratios after 12 months of follow-up, irrespective of main treatment allocation (table 2) . The diff erences in NTx to creatinine ratio between randomisation groups were signifi cant after 12 months of follow-up in stratum II (p<0·0001). We noted decreases in NTx to creatinine concentrations were observed for both treatment groups for women in stratum III, but the diff erence was not signifi cant (table 2) . 639 (45%) of 1410 women in the IBIS-II bone substudy had adverse events (table 3) . Incidence did not diff er between treatment allocations within each stratum. No serious adverse events, such as osteonecrosis of the jaw or serious gastrointestinal problems, were reported after 3 years of follow-up with risedronate. Only 85 women had a treatment interruption from risedronate between baseline and 36 months (median 3 weeks [IQR 2-5]; 65 women in stratum II and 20 women in stratum III). By 36 months of follow-up, two women in stratum I (one anastrozole, one placebo) and 23 women in stratum II (six placebo/placebo, two placebo/risedronate, ten anastrozole/placebo, and fi ve anastrozole/risedronate) developed osteoporosis and subsequently stopped trial medication to start open-label bisphosphonates. Overall, 128 fractures were reported by 109 women in the bone substudy (44 women in stratum I, 51 women in stratum II, and 14 women in stratum III). 57 (8%) of 711 women randomly allocated to anastrozole reported at least one fracture compared with 52 (7%) of 699 in the placebo group. The incidence rate for fractures in the anastrozole arm was 13·7 per 1000 woman-years compared with 12·6 per 1000 woman-years in the placebo arm (p=0·70). The number of fractures is too small at present to report stratum specifi c data, and further follow-up is needed.
Discussion
The mean percentage BMD loss in women on placebo in our study is similar to that reported in the overall population of similar age. 17 The IBIS-II results confi rm that 3 years of anastrozole decreases BMD at the lumbar spine or total hip in healthy postmenopausal women, as previously reported (panel). 13 More importantly, our results show that risedronate counterbalances BMD loss induced by anastrozole in women with osteopenia or osteoporosis. Similar fi ndings have been reported by two smaller studies in patients with breast cancer. 18, 19 Both trials showed that the addition of a bisphosphonate normalises bone turnover in such patients receiving anastrozole after 2 years. Longer follow-up is needed to assess the fracture risk in healthy postmenopausal women receiving anastrozole. Risedronate was well tolerated and no serious adverse events, such as osteonecrosis of the jaw or serious gastrointestinal problems, were reported after 3 years of follow-up.
Bisphosphonates are well established drugs for the prevention of bone loss and reduction of fractures in postmenopausal women and men with osteoporosis. 2, 20, 21 Oral and intravenous bisphosphonates signifi cantly reduce the incidence of vertebral and non-vertebral fractures. 22 In the adjuvant setting, anastrozole, letrozole, and exemestane have all been assessed in postmenopausal women with early breast cancer. [23] [24] [25] [26] These trials have all shown signifi cant BMD loss with these drugs, but have in common that the comparator was tamoxifen, which has been shown to have a benefi cial eff ect on bone. 6, 7, 9 Zoledronic acid can prevent BMD loss induced by letrozole or anastrozole in postmenopausal women with breast cancer. [27] [28] [29] A small study assessing risedronate in women with breast cancer receiving anastrozole showed that this drug was eff ective in preventing anastrozole induced bone loss. 30 In a large review, the European guidelines 31 for the management of aromatase inhibitor induced bone loss concluded that the use of bisphosphonates for treatment of osteoporosis in postmenopausal women with breast cancer is safe and that these drugs are eff ective in the prevention of BMD loss because of endocrine therapy.
In the preventive setting, the bone substudy of the MAP.3 trial, 13 which compared exemestane with placebo, recently reported their results on bone density changes in a subgroup of women. Their primary endpoint was the comparison of percentage change in total volumetric BMD at the distal radius between baseline and 2 years of follow-up by quantitative CT. However, they also reported on BMD changes at the lumbar spine and total hip by DXA as a secondary objective, and reported that women 
Systematic review
We searched PubMed for randomly allocated trials in the preventive setting published in English before May 30, 2014 , that investigated a bisphosphonate in women at high risk of breast cancer treated with an aromatase inhibitor. We used the search terms "breast cancer", "prevention", "high risk", "aromatase inhibitor", and "bisphosphonate". We identifi ed no other breast cancer prevention trials investigating the eff ect of a bisphosphonate in combination with an aromatase inhibitor in postmenopausal women at high risk of development of the disease. However, we identifi ed several trials in the adjuvant setting. We identifi ed one other prevention trial 13 in postmenopausal women comparing exemestane with placebo that reported on bone mineral density changes in this study group, but did not investigate the use of a bisphosphonate.
Interpretation
Results from our trial provide the fi rst evidence that risedronate prevents anastrozoleinduced bone mineral density loss in postmenopausal women at high risk of development of breast cancer with osteopenia or osteoporosis. Risedronate was well tolerated and no serious adverse events associated with this drug were reported. Because aromatase inhibitors have emerged as a treatment option for the reduction of breast cancer risk for postmenopausal women, the concomitant use of a bisphosphonate is inevitable in this setting. However, long-term follow-up is required for the assessment of risedronate on fracture risk and for overall bone mineral density changes over the course of 5 years of anastrozole use. randomly allocated to exemestane had a signifi cant decrease in BMD at all sites compared with placebo after 2 years of follow-up. The MAP.3 trial did not assess the use of a bisphosphonate in women receiving exemestane and therefore a direct comparison between the two trials in that respect is not possible.
Anastrozole resulted in signifi cant increases in bone turnover whereas women on placebo showed little change after 12 months in those with healthy bone or osteopenic women and not receiving risedronate. Other studies, in the adjuvant setting, have also shown that aromatase inhibitors are associated with higher concentrations of bone resorption makers. 7, 8, 32 By contrast, those women who were randomly allocated to risedronate in stratum II or osteoporotic women (stratum III) receiving risedronate showed signifi cant decreases in NTx to creatinine ratio by 12 months of follow-up.
Strengths of our analysis include an overall large sample size (1410 women), with a large proportion of women with osteopenia, long follow-up of 3 years, and a population that came from a large prevention trial with excellent clinical records. Furthermore, this trial is the fi rst time that a bisphosphonate has been compared with a placebo in healthy postmenopausal woman at risk of development of breast cancer who are taking anastrozole as a preventive drug. This analysis reports on the 3 year BMD changes, but we will be able to present results after 5 years of treatment and are in the process of obtaining a DXA scan 2 years after treatment cessation to investigate whether BMD loss induced by anastrozole is regained.
Limitations of our study include the incomplete set of BMD data at 36 months (903 [64%] of 1410 women). Specifi cally for our primary objective, the number of women included in the analysis was small, but nevertheless we detected signifi cant diff erences between the treatment groups. This fi nding is mainly attributable to withdrawal from the main IBIS-II study in the fi rst 3 years and therefore our results might not be representative for the whole study population. However, only 5·4% of women withdrew from the bone substudy without fi rst leaving the main study. A few participants were lost to follow-up because centres changed their DXA scanner to a diff erent manufacturer. Wherever possible, this problem was mitigated by arranging for the women to be scanned on a similar machine at a diff erent hospital. A further limitation of this study is the insuffi cient followup length for fracture risk assessment. DXA is the standard clinical technique for skeletal assessment of BMD changes and fracture risk, but does not take into account bone structure and micro architecture of the bone. Bone structure, especially cortical structure of the bone, probably plays an important part in determination of bone strength, 13, 33, 34 but assessment of these bone structure changes was not possible.
To our knowledge, this analysis was the fi rst to investigate the eff ect of risedronate on anastrozoleinduced bone loss in healthy postmenopausal women in a placebo-controlled trial. Our fi ndings confi rm BMD loss induced by anastrozole in healthy postmenopausal women in the preventive setting. However, we also showed that risedronate counterbalances the eff ect of anastrozole-induced bone loss in osteopenic and osteoporotic women. Longer follow-up is needed to assess the risk of fracture with anastrozole in healthy postmenopausal women. Nevertheless, careful monitoring of bone density by DXA scans and the use of a bisphosphonate can control BMD loss induced by anastrozole in the preventive setting.
